Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513
ARTICLE
Year: 2021   |   Volume: 10   |   Issue: 6   |   Page: 336-336     View issue
Platelet endothelial aggregation receptor 1 polymorphisms and idiopathic thrombocytopenic purpura
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Dear Editor,

We would like to share ideas on the publication “Role of platelet endothelial aggregation receptor 1 polymorphisms in idiopathic thrombocytopenic purpura: Is there an association?[1]” Najafi et al. concluded that “There was no association between rs12041331 and rs12566888 with platelet parameters in ITP patients and the severity of …….[1]” In fact, the platelet endothelial aggregation receptor 1 polymorphism results in a molecular change and might further affect biological interaction. However, there are also other confounding factors, including other genetic polymorphisms, which can affect phenotypic expression in idiopathic thrombocytopenic purpura (ITP). Examples of other genetic polymorphisms that might affect ITP are D28, ICOS, PD1, TNFSF4, DNAM1, TIM3, CTLA4, and LAG polymorphisms.[2] Further studies to assess effect of other confounding genetic factors are interesting.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

Najafi S, Jalali Far MA, Kaydani GA, Jaseb K, Saki N. Role of platelet endothelial aggregation receptor 1 polymorphisms in idiopathic thrombocytopenic purpura: Is there an association? Clin Cancer Investig J 2021;10:227-33.

Wang S, Zhang X, Leng S, Xu Q, Sheng Z, Zhang Y, et al. Immune checkpoint-related gene polymorphisms are associated with primary immune thrombocytopenia. Front Immunol 2020;11:615941.

© Clinical Cancer Investigation Journal
Online since 01 December, 2011
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513